{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:40:36Z","timestamp":1781646036367,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070448"],"award-info":[{"award-number":["82070448"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970227"],"award-info":[{"award-number":["81970227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LZ20H020001"],"award-info":[{"award-number":["LZ20H020001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The efficacy of stem cell therapy for ischemia repair has been limited by low cell retention rate. Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-\u03b2 super family, which has multiple effects on development, physiology and diseases. The objective of the study is to investigate whether GDF11 could affect the efficacy of stem cell transplantation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We explored the effects of GDF11 on proangiogenic activities of mesenchymal stem cells (MSCs) for angiogenic therapy in vitro and in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mouse bone marrow-derived MSCs were transduced with lentiviral vector to overexpress GDF11 (MSC<jats:sup>GDF11<\/jats:sup>). After exposed to hypoxia and serum deprivation for 48\u00a0h, MSC<jats:sup>GDF11<\/jats:sup> were significantly better in viability than control MSCs (MSC<jats:sup>vector<\/jats:sup>). MSC<jats:sup>GDF11<\/jats:sup> also had higher mobility and better angiogenic paracrine effects. The cytokine antibody array showed more angiogenic cytokines in the conditioned medium of MSC<jats:sup>GDF11<\/jats:sup> than that of MSC<jats:sup>vector<\/jats:sup>, such as epidermal growth factor, platelet-derived growth factor-BB, placenta growth factor. When MSCs (1\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> cells in 50\u00a0\u03bcl) were injected into ischemic hindlimb of mice after femoral artery ligation, MSC<jats:sup>GDF11<\/jats:sup> had higher retention rate in the muscle than control MSCs. Injection of MSC<jats:sup>GDF11<\/jats:sup> resulted in better blood reperfusion and limb salvage than that of control MSCs after 14\u00a0days. Significantly more CD31<jats:sup>+<\/jats:sup> endothelial cells and \u03b1-SMA\u2009+\u2009smooth muscle cells were detected in the ischemic muscles that received MSC<jats:sup>GDF11<\/jats:sup>. The effects of GDF11 were through activating TGF-\u03b2 receptor and PI3K\/Akt signaling pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study demonstrated an essential role of GDF11 in promoting therapeutic functions of MSCs for ischemic diseases by enhancing MSC viability, mobility, and angiogenic paracrine functions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-021-02519-y","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T11:27:44Z","timestamp":1628767664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["RETRACTED ARTICLE: GDF11 enhances therapeutic functions of mesenchymal stem cells for angiogenesis"],"prefix":"10.1186","volume":"12","author":[{"given":"Chi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0521-8933","authenticated-orcid":false,"given":"Hong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2519_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-bioeng-070909-105309","volume":"12","author":"B Parekkadan","year":"2010","unstructured":"Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010;12:87\u2013117.","journal-title":"Annu Rev Biomed Eng"},{"key":"2519_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCRESAHA.115.306850","volume":"117","author":"BR Weil","year":"2015","unstructured":"Weil BR, Suzuki G, Leiker MM, Fallavollita JA, Canty JM. Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere-derived cells in swine with hibernating myocardium. Circ Res. 2015;117:634\u201344.","journal-title":"Circ Res"},{"key":"2519_CR3","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","volume":"54","author":"JM Hare","year":"2009","unstructured":"Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"2519_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2174\/1574888X11308050004","volume":"8","author":"MS Choudhery","year":"2013","unstructured":"Choudhery MS, Badowski M, Muise A, Harris DT. Utility of cryopreserved umbilical cord tissue for regenerative medicine. Curr Stem Cell Res Ther. 2013;8:370\u201380.","journal-title":"Curr Stem Cell Res Ther"},{"key":"2519_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jcsm.12416","volume":"10","author":"TH Qazi","year":"2019","unstructured":"Qazi TH, Duda GN, Ort MJ, Perka C, Geissler S, Winkler T. Cell therapy to improve regeneration of skeletal muscle injuries. J Cachexia Sarcopenia Muscle. 2019;10:501\u201316.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2519_CR6","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/mt.2014.161","volume":"22","author":"H Gremmels","year":"2014","unstructured":"Gremmels H, Teraa M, Quax PH, den Ouden K, Fledderus JO, Verhaar MC. Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls. Mol Ther. 2014;22:1960\u201370.","journal-title":"Mol Ther"},{"key":"2519_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/cells10030641","volume":"10","author":"D Zhu","year":"2021","unstructured":"Zhu D, Cheng K. Cardiac cell therapy for heart repair: should the cells be left out? Cells. 2021;10:641.","journal-title":"Cells"},{"key":"2519_CR8","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/cells8121530","volume":"8","author":"M Samak","year":"2019","unstructured":"Samak M, Hinkel R. Stem cells in cardiovascular medicine: historical overview and future prospects. Cells. 2019;8:1530.","journal-title":"Cells"},{"key":"2519_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1634\/stemcells.2008-0520","volume":"27","author":"IB Copland","year":"2009","unstructured":"Copland IB, Lord-Dufour S, Cuerquis J, Coutu DL, Annabi B, Wang E, et al. Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition. Stem Cells. 2009;27:467\u201377.","journal-title":"Stem Cells"},{"key":"2519_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1161\/ATVBAHA.116.307126","volume":"36","author":"Q Ma","year":"2016","unstructured":"Ma Q, Xia X, Tao Q, Lu K, Shen J, Xu Q, et al. Profound actions of an agonist of growth hormone-releasing hormone on angiogenic therapy by mesenchymal stem cells. Arterioscler Thromb Vasc Biol. 2016;36:663\u201372.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2519_CR11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/CIRCRESAHA.115.307516","volume":"118","author":"X Hu","year":"2016","unstructured":"Hu X, Xu Y, Zhong Z, Wu Y, Zhao J, Wang Y, et al. A large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman primates: paracrine activity without remuscularization. Circ Res. 2016;118:970\u201383.","journal-title":"Circ Res"},{"key":"2519_CR12","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/jor.22130","volume":"30","author":"D Steiner","year":"2012","unstructured":"Steiner D, Lampert F, Stark GB, Finkenzeller G. Effects of endothelial cells on proliferation and survival of human mesenchymal stem cells and primary osteoblasts. J Orthop Res. 2012;30:1682\u20139.","journal-title":"J Orthop Res"},{"key":"2519_CR13","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1002\/jcb.21935","volume":"105","author":"BD Cook","year":"2008","unstructured":"Cook BD, Ferrari G, Pintucci G, Mignatti P. Tgf-beta1 induces rearrangement of flk-1-ve-cadherin-beta-catenin complex at the adherens junction through vegf-mediated signaling. J Cell Biochem. 2008;105:1367\u201373.","journal-title":"J Cell Biochem"},{"key":"2519_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581\u2013611.","journal-title":"Endocr Rev"},{"key":"2519_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.matbio.2012.11.004","volume":"32","author":"EP Sproul","year":"2013","unstructured":"Sproul EP, Argraves WS. A cytokine axis regulates elastin formation and degradation. Matrix Biol. 2013;32:86\u201394.","journal-title":"Matrix Biol"},{"key":"2519_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbcan.2006.06.004","volume":"1775","author":"K Pardali","year":"2007","unstructured":"Pardali K, Moustakas A. Actions of tgf-\u03b2 as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta Rev Cancer. 2007;1775:21\u201362.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2519_CR17","doi-asserted-by":"crossref","unstructured":"Harper SC, Brack A, MacDonnell S, Franti M, Olwin BB, Bailey BA, et al. Is growth differentiation factor 11 a realistic therapeutic for aging-dependent muscle defects? Circ Res. 2016;118:1143\u201350 (discussion 1150).","DOI":"10.1161\/CIRCRESAHA.116.307962"},{"key":"2519_CR18","doi-asserted-by":"publisher","first-page":"81604","DOI":"10.18632\/oncotarget.20258","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Wei Y, Liu D, Liu F, Li X, Pan L, et al. Role of growth differentiation factor 11 in development, physiology and disease. Oncotarget. 2017;8:81604\u201316.","journal-title":"Oncotarget"},{"key":"2519_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.1251141","volume":"344","author":"L Katsimpardi","year":"2014","unstructured":"Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344:630\u20134.","journal-title":"Science"},{"key":"2519_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pharmthera.2015.10.006","volume":"156","author":"L Rochette","year":"2015","unstructured":"Rochette L, Zeller M, Cottin Y, Vergely C. Growth and differentiation factor 11 (gdf11): functions in the regulation of erythropoiesis and cardiac regeneration. Pharmacol Ther. 2015;156:26\u201333.","journal-title":"Pharmacol Ther"},{"key":"2519_CR21","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2013.04.015","volume":"153","author":"FS Loffredo","year":"2013","unstructured":"Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153:828\u201339.","journal-title":"Cell"},{"key":"2519_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1126\/science.1251152","volume":"344","author":"M Sinha","year":"2014","unstructured":"Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, et al. Restoring systemic gdf11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344:649\u201352.","journal-title":"Science"},{"key":"2519_CR23","doi-asserted-by":"publisher","first-page":"8703","DOI":"10.1111\/jcmm.15502","volume":"24","author":"C Zhang","year":"2020","unstructured":"Zhang C, Lin Y, Liu Q, He J, Xiang P, Wang D, et al. Growth differentiation factor 11 promotes differentiation of mscs into endothelial-like cells for angiogenesis. J Cell Mol Med. 2020;24:8703\u201317.","journal-title":"J Cell Mol Med"},{"key":"2519_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/sctm.20-0005","volume":"9","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhu J, Zhang N, Liu Q, Wang Y, Hu X, et al. Gdf11 enhances therapeutic efficacy of mesenchymal stem cells for myocardial infarction via yme1l-mediated opa1 processing. Stem Cells Transl Med. 2020;9:1257\u201371.","journal-title":"Stem Cells Transl Med"},{"key":"2519_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11626-009-9198-1","volume":"45","author":"MB Eslaminejad","year":"2009","unstructured":"Eslaminejad MB, Nadri S. Murine mesenchymal stem cell isolated and expanded in low and high density culture system: Surface antigen expression and osteogenic culture mineralization. Vitro Cell Dev Biol Anim. 2009;45:451\u20139.","journal-title":"Vitro Cell Dev Biol Anim"},{"key":"2519_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tins.2007.06.009","volume":"30","author":"E Sena","year":"2007","unstructured":"Sena E, van der Worp H, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007;30:433\u20139.","journal-title":"Trends Neurosci"},{"key":"2519_CR27","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1073\/pnas.1916034117","volume":"117","author":"J Suh","year":"2020","unstructured":"Suh J, Kim N-K, Lee S-H, Eom J-H, Lee Y, Park J-C, et al. Gdf11 promotes osteogenesis as opposed to mstn, and follistatin, a mstn\/gdf11 inhibitor, increases muscle mass but weakens bone. Proc Natl Acad Sci. 2020;117:4910\u201320.","journal-title":"Proc Natl Acad Sci"},{"key":"2519_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/ijms19051508","volume":"19","author":"J Duran","year":"2018","unstructured":"Duran J, Troncoso MF, Lagos D, Ramos S, Marin G, Estrada M. Gdf11 modulates ca(2+)-dependent smad2\/3 signaling to prevent cardiomyocyte hypertrophy. Int J Mol Sci. 2018;19:1508.","journal-title":"Int J Mol Sci"},{"key":"2519_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00395-019-0728-z","volume":"114","author":"H Su","year":"2019","unstructured":"Su H, Liao J, Wang Y, Chen K, Lin C, Lee I, et al. Exogenous gdf11 attenuates non-canonical tgf-\u03b2 signaling to protect the heart from acute myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2019;114:20.","journal-title":"Basic Res Cardiol"},{"key":"2519_CR30","doi-asserted-by":"publisher","first-page":"12063","DOI":"10.18632\/oncotarget.7642","volume":"7","author":"YH Zhang","year":"2016","unstructured":"Zhang YH, Cheng F, Du XT, Gao JL, Xiao XL, Li N, et al. Gdf11\/bmp11 activates both smad1\/5\/8 and smad2\/3 signals but shows no significant effect on proliferation and migration of human umbilical vein endothelial cells. Oncotarget. 2016;7:12063\u201374.","journal-title":"Oncotarget"},{"key":"2519_CR31","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.2337\/db17-1583","volume":"67","author":"J Zhang","year":"2018","unstructured":"Zhang J, Li Y, Li H, Zhu B, Wang L, Guo B, et al. Gdf11 improves angiogenic function of epcs in diabetic limb ischemia. Diabetes. 2018;67:2084\u201395.","journal-title":"Diabetes"},{"key":"2519_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCRESAHA.115.307861","volume":"118","author":"EM McNally","year":"2016","unstructured":"McNally EM. Questions and answers about myostatin, gdf11, and the aging heart. Circ Res. 2016;118:6\u20138.","journal-title":"Circ Res"},{"key":"2519_CR33","doi-asserted-by":"crossref","unstructured":"Walker RG, Poggioli T, Katsimpardi L, Buchanan SM, Oh J, Wattrus S, et al. Biochemistry and biology of gdf11 and myostatin: similarities, differences, and questions for future investigation. Circ Res. 2016;118:1125\u201341 (discussion 1142).","DOI":"10.1161\/CIRCRESAHA.116.308391"},{"key":"2519_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/cr.2008.328","volume":"19","author":"YE Zhang","year":"2009","unstructured":"Zhang YE. Non-smad pathways in tgf-beta signaling. Cell Res. 2009;19:128\u201339.","journal-title":"Cell Res"},{"key":"2519_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.celrep.2014.05.001","volume":"7","author":"F Demontis","year":"2014","unstructured":"Demontis F, Patel VK, Swindell WR, Perrimon N. Intertissue control of the nucleolus via a myokine-dependent longevity pathway. Cell Rep. 2014;7:1481\u201394.","journal-title":"Cell Rep"},{"key":"2519_CR36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/ten.teb.2012.0672","volume":"19","author":"J Chen","year":"2013","unstructured":"Chen J, Crawford R, Chen C, Xiao Y. The key regulatory roles of the pi3k\/akt signaling pathway in the functionalities of mesenchymal stem cells and applications in tissue regeneration. Tissue Eng Part B Rev. 2013;19:516\u201328.","journal-title":"Tissue Eng Part B Rev"},{"key":"2519_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.semcancer.2015.07.003","volume":"35","author":"M Toulany","year":"2015","unstructured":"Toulany M, Rodemann H. Phosphatidylinositol 3-kinase\/akt signaling as a key mediator of tumor cell responsiveness to radiation. Semin Cancer Biol. 2015;35:180\u201390.","journal-title":"Semin Cancer Biol"},{"key":"2519_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajmg.c.31531","volume":"172","author":"K Keppler-Noreuil","year":"2016","unstructured":"Keppler-Noreuil K, Parker V, Darling T, Martinez-Agosto J. Somatic overgrowth disorders of the pi3k\/akt\/mtor pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet. 2016;172:402\u201321.","journal-title":"Am J Med Genet C Semin Med Genet"}],"updated-by":[{"DOI":"10.1186\/s13287-023-03247-1","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"record-id":"42362"},{"DOI":"10.1186\/s13287-023-03247-1","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000}}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02519-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-021-02519-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02519-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T17:05:22Z","timestamp":1675184722000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02519-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2519"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02519-y","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13287-023-03247-1","URL":"https:\/\/doi.org\/10.1186\/s13287-023-03247-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal protocols used in this study and the research proposal for use of human samples were approved by the Second Affiliated Hospital Research Ethics Committee of Zhejiang University and in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The HUVEC collection and the related experiments were approved by the Ethics Committee of National Engineering Research Center of Cell Products, State Key Laboratory of Experimental Hematology, Institute of Hematology. Animal study protocols were designed in accordance with guidelines for the use of laboratory animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}